Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

CV Sciences, Inc. (CVSI)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1949-0.0100 (-4.88%)
At close: 12:59PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2049
Open0.2049
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1866 - 0.2049
52 Week Range0.1700 - 1.1200
Volume173,995
Avg. Volume375,512
Market Cap21.573M
Beta (5Y Monthly)0.81
PE Ratio (TTM)N/A
EPS (TTM)-0.1520
Earnings DateNov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.39
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for CVSI

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CV SCIENCES INC
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverThis edition features European banks; California utilities; traditional payment firms; and notes from Johnson & Johnson, Green Thumb Industries, and new coverage Lithium Americas.
    Rating
    Fair Value
    Economic Moat
    16 days agoMorningstar
View more
  • Zacks

    Here's Why CV Sciences, Inc. (CVSI) Looks Ripe for Bottom Fishing

    CV Sciences, Inc. (CVSI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

  • GlobeNewswire

    CV Sciences, Inc. Announces Convertible Note Financing

    SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it has entered into a securities purchase agreement with an institutional investor, providing for the sale and issuance of convertible notes due 2022 in the aggregate original principal amount of $1.06 million. Upon our filing with the Securities and Exchange Commission of a

  • GlobeNewswire

    CV Sciences, Inc. Reports Third Quarter 2021 Financial Results

    SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended September 30, 2021. Third Quarter 2021 and Recent Financial and Operating Highlights Revenue of $5.1 million for third quarter of 2021, compared to $5.6 million for the third quarter of 2020;Gross margin of 46.2% for third quarter of 20

Advertisement
Advertisement